ANIX

Company Overview — What Does Anixa Biosciences Inc Do?

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Anixa Biosciences Inc (ANIX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Amit D. Kumar and employs approximately 5 people, headquartered in Los Angeles, California. With a market capitalization of $91M, ANIX is one of the notable companies in the Healthcare sector.

Anixa Biosciences Inc (ANIX) Stock Rating — Reduce (April 2026)

As of April 2026, Anixa Biosciences Inc receives a Reduce rating with a composite score of 30.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ANIX ranks #3,781 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Anixa Biosciences Inc ranks #635 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ANIX Stock Price and 52-Week Range

Anixa Biosciences Inc (ANIX) currently trades at $2.80. The stock gained $0.06 (2.3%) in the most recent trading session. The 52-week high for ANIX is $5.46, which means the stock is currently trading -48.6% from its annual peak. The 52-week low is $2.33, putting the stock 20.3% above its annual trough. Recent trading volume was 171K shares, suggesting relatively thin trading activity.

Is ANIX Overvalued or Undervalued? — Valuation Analysis

Anixa Biosciences Inc (ANIX) carries a value factor score of 30/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 6.51x, versus the sector average of 2.75x.

At current multiples, Anixa Biosciences Inc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Anixa Biosciences Inc Profitability — ROE, Margins, and Quality Score

Anixa Biosciences Inc (ANIX) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -78.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -71.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ANIX Debt, Balance Sheet, and Financial Health

Anixa Biosciences Inc has a debt-to-equity ratio of 10.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 12.18x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $1M.

ANIX has a beta of 1.29, meaning it is more volatile than the broader market — a $10,000 investment in ANIX would be expected to move 28.9% more than the S&P 500 on any given day. The stability factor score for Anixa Biosciences Inc is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Anixa Biosciences Inc Revenue and Earnings History — Quarterly Trend

In TTM 2026, Anixa Biosciences Inc reported revenue of $0 and earnings per share (EPS) of $-0.08. Net income for the quarter was $-11M. Operating income came in at $-12M.

In Q1 2026, Anixa Biosciences Inc reported revenue of $0 and earnings per share (EPS) of $-0.08. Net income for the quarter was $-3M. Operating income came in at $-3M.

In FY 2025, Anixa Biosciences Inc reported revenue of $0 and earnings per share (EPS) of $-0.34. Net income for the quarter was $-11M. Operating income came in at $-12M.

In Q3 2025, Anixa Biosciences Inc reported revenue of $0 and earnings per share (EPS) of $-0.07. Net income for the quarter was $-2M. Operating income came in at $-2M.

Over the past 8 quarters, Anixa Biosciences Inc has experienced revenue contraction from $0 to $0. Investors analyzing ANIX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ANIX Dividend Yield and Income Analysis

Anixa Biosciences Inc (ANIX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ANIX Momentum and Technical Analysis Profile

Anixa Biosciences Inc (ANIX) has a momentum factor score of 30/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 51/100 reflects moderate short selling activity.

ANIX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Anixa Biosciences Inc (ANIX) ranks #635 out of 838 stocks based on the Blank Capital composite score. This places ANIX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ANIX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ANIX vs S&P 500 (SPY) comparison to assess how Anixa Biosciences Inc stacks up against the broader market across all factor dimensions.

ANIX Next Earnings Date

No upcoming earnings date has been announced for Anixa Biosciences Inc (ANIX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ANIX? — Investment Thesis Summary

The quantitative profile for Anixa Biosciences Inc suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 30/100 indicates premium valuation. Momentum is weak at 30/100, a headwind for near-term performance. High volatility (stability score 35/100) increases portfolio risk.

In summary, Anixa Biosciences Inc (ANIX) earns a Reduce rating with a composite score of 30.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ANIX stock.

Related Resources for ANIX Investors

Explore more research and tools: ANIX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ANIX head-to-head with peers: ANIX vs AZN, ANIX vs SLGL, ANIX vs VMD.